• In late May and early June 2026, Abbott highlighted new data showing rising, often-missed diabetic ketoacidosis cases and secured CE Mark approval in Europe for Libre Duo and Libre Duo 10 Day, its first-of-its-kind dual glucose‑ketone continuous monitoring systems, while awaiting U.S. FDA clearance.
• The combination of alarming national trends in DKA-related hospitalizations and Abbott’s dual-analyte sensor positions the company to address a critical gap in diabetes care.
• We’ll now examine how Abbott’s dual glucose‑ketone technology and focus on earlier DKA detection may influence its broader investment narrative.

Find 49 companies with promising cash flow potential yet trading below their fair value.

Abbott Laboratories Investment Narrative Recap

To own Abbott, you need to believe in its diversified healthcare model and its ability to keep innovating in core franchises like diabetes care and diagnostics. The latest dual glucose ketone data and CE Mark for Libre Duo align with that story, but they do not change the near term focus on stabilizing Diagnostics after COVID testing declines or the key risk around pricing pressure in diabetes devices.

Among recent announcements, the American Cancer Society’s reaffirmation of Cologuard and Cologuard Plus as preferred noninvasive colorectal cancer screening options is especially relevant. It underlines Abbott’s broader bet on clinically validated, guideline supported tools that can sustain growth beyond Libre, even as competitive and reimbursement pressures build around continuous glucose monitoring.

However, while Libre Duo may help differentiation today, competitive bidding and rising CGM competition in the US could still pressure pricing in ways investors should be aware of...

Abbott Laboratories’ narrative projects $59.6 billion revenue and $9.5 billion earnings by 2029. This requires 9.7% yearly revenue growth and a $3.2 billion earnings increase from $6.3 billion today.

Uncover how Abbott Laboratories' forecasts yield a $117.29 fair value, a 29% upside to its current price.

Exploring Other Perspectives

Six members of the Simply Wall St Community currently see Abbott’s fair value between US$117.29 and US$140.18, well above the recent share price. You should weigh those views against risks like intensifying CGM competition and pricing pressure that could influence Abbott’s ability to convert its innovation pipeline into sustained financial performance.

Explore 6 other fair value estimates on Abbott Laboratories - why the stock might be worth as much as 54% more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Abbott Laboratories research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Abbott Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Abbott Laboratories' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Explore 30 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.